FDA Approves Prescription Weight Loss Injection Zepbound™
Studies show weight loss injection can decrease total body weight by more than 20%
November 8th, 2023: Today the FDA approved Zepbound™, Eli Lilly’s prescription weight loss injection. Zepbound™ is a weekly, self-administered injection used for the treatment of chronic weight management in adults with obesity. Tirzepatide, the active ingredient in Zepbound™ works by altering your hunger hormones, decreasing the amount of food eaten and also helping you to feel fuller for longer periods of time. Tirzepatide has been previously FDA-approved in the treatment of diabetes under the brand name Mounjaro™. Studies have shown that Zepbound™ can help patients lose more than 20% of their body weight.
At New Jersey Bariatric Center® we pair FDA-approved prescription weight loss medication with support from our team, healthy eating education, exercise and lifestyle modifications. This comprehensive approach helps to set the foundation for more sustainable weight loss and gives you lifelong tools that help you achieve your healthiest weight. We know weight loss goals are successfully achieved when doctor visits and weight loss medication are combined with long-term support and consistent nutrition education and counseling.
According to the FDA, to qualify for Zepbound™, you must be over the age of 18 and meet the following requirements:
- Have a BMI of 30 or greater, or
- Have a BMI of 27 or more with at least one weight-related medical condition such as high blood pressure, type 2 diabetes or high cholesterol.
Eli Lilly expects that Zepbound™ will be available by the end of the year. Once it becomes available at NJBC we will post an update.
For more information, call our office at 908-481-1270. To request an appointment, click here.